Buzz Stocks: BlackBerry, Dow Chemical, Orexigen

Today's stocks to watch include BlackBerry Ltd (BBRY), Dow Chemical Co (DOW), and Orexigen Therapeutics, Inc. (OREX)

Mar 27, 2015 at 9:30 AM
facebook X logo linkedin


U.S. futures are trading lower ahead of the open, with investors eyeing today's reading on gross domestic product (GDP) and a speech from Fed Chair Janet Yellen. Among the equities in focus are smartphone maker BlackBerry Ltd (NASDAQ:BBRY), science and technology giant Dow Chemical Co (NYSE:DOW), and biotech name Orexigen Therapeutics, Inc. (NASDAQ:OREX).

  • BBRY is making a strong push higher in electronic trading, after the company's fourth-quarter profit beat analysts' expectations. The shares are pointed 6.2% higher ahead of the open, as they try to gain back some of their 15.3% year-to-date deficit, following yesterday's close at $9.30. If BlackBerry Ltd can sustain this morning's momentum, the equity could be looking at additional upside, given the amount of pessimism surrounding it. For instance, put buying has picked up during the past two weeks at the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX). The stock's 10-day put/call volume ratio across these exchanges is 0.36 -- which lands in the 72nd percentile of its annual range. Elsewhere, nearly one-fifth of BBRY's float is sold short, representing over eight sessions' worth of trading, at normal daily volumes. A reversal of sentiment in and out of the options pits could give the security a spark.

  • DOW has gained 3.5% in electronic trading, after announcing it will sell most of its chlorine business to sector peer Olin Corporation (NYSE:OLN) -- in a transaction valued at roughly $5 billion. Dow Chemical Co finished yesterday at $46.44, and has now added nearly 11% since its 2015 low of $41.95 on Jan. 14. Still, analysts aren't sold on the equity just yet. Of the 18 brokerage firms covering DOW, 11 rate it a "hold" or worse.

  • OREX is poised to jump 7.6% out of the gate, after the company's obesity drug, Mysimba, was approved for marketing authorization by the European Commission. In the stock's options pits, OREX's Schaeffer's put/call open interest ratio (SOIR) of 1.01 rests at an annual high, meaning short-term speculators are more put-heavy now than at any other time during the past year. On the Street, analysts have taken a bullish stance. All six of the brokerage firms covering Orexigen Therapeutics, Inc. rate it a "buy" or better. OREX has done its best to live up to these expectations, adding 11.2% year-over-year, settling at $7.25 yesterday.
 

Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on C3.ai calls
238.5% GAIN on Oracle calls

 
 
 


 
 

Rainmaker Ads CGI